Background
==========

Breast cancer (BC) is the most common female malignancy around the world, and its high morbidity and mortality rates are mainly due to metastasis \[[@b1-medscimonit-25-3298],[@b2-medscimonit-25-3298]\]. In China, breast cancer leads to approximately 45,000 deaths among females every year and is a major threat to human health \[[@b3-medscimonit-25-3298]\]. Recently, the outcomes and quality of life of BC patients have been improved due to detection at an early stage, suitable staging, risk evaluation, clinical outcome estimation, and surveillance \[[@b4-medscimonit-25-3298]\]. Clinically, this can be accomplished by evaluating biomarkers in tumor tissues and blood samples. There are some advantages of using circulating biomarkers in blood, such as being minimally-invasive and the ability to obtain multiple specimens at the same time. Unfortunately, at present, the conventional biomarkers have low diagnostic accuracy due to the advanced stages and the heterogeneity of breast cancer \[[@b5-medscimonit-25-3298]--[@b8-medscimonit-25-3298]\]. Therefore, it is of great importance to find improved molecular markers that can more accurately stratify BC patients, thus facilitating the identification of the ideal approaches of treatment for each individual patient \[[@b9-medscimonit-25-3298],[@b10-medscimonit-25-3298]\].

*Actinin-4* (gene name *ACTN4*) was identified in 1998 as an actin-binding protein that is closely associated with enhanced cell motility and cancer invasion and metastasis \[[@b11-medscimonit-25-3298],[@b12-medscimonit-25-3298]\]. During the development of human cancers, the *actinin-4* protein level is markedly increased in malignant phenotypes of cancer \[[@b11-medscimonit-25-3298]\]. The *actinin-4* protein level is closely related to the poor prognosis in human cancers, such as thyroid cancer \[[@b13-medscimonit-25-3298]\], lung cancer \[[@b14-medscimonit-25-3298],[@b15-medscimonit-25-3298]\], and salivary gland carcinoma \[[@b16-medscimonit-25-3298]\]. Additionally, in lung adenocarcinoma, immunohistochemistry showed that actinin-4 protein is overexpressed and can predict the efficacy of adjuvant chemotherapy for resection \[[@b17-medscimonit-25-3298]\]. However, the expression of *ACTN4* and its clinical outcome in BC has not yet been investigated.

Therefore, in the present study, we examined the *ACTN4* levels in blood specimens from patients with breast cancer using qRT-PCR. Additionally, we investigated the correlation between *ACTN4* levels and clinicopathologic features and assessed the diagnostic values of *ACTN4*.

Material and Methods
====================

Patients and sample collections
-------------------------------

This research was authorized by the Ethics Committee of the College of Medicine, Henan University. Informed written consent from each patient and local ethics committee approval was obtained before starting data collection.

The present study was conducted on 128 female subjects aged 17--70 years. Blood was obtained from patients when diagnosed, before they received any anti-cancer therapies or surgery. Peripheral blood of 96 healthy female volunteers without any other diseases, such as tumors, autoimmune diseases, or inflammation breast cancer was obtained as a control group (age range, 18--69 years).

The blood samples were stored at 4°C for 1 h. After centrifuging for 5 min at 2000×g, serum was collected and centrifuged again at 12 000g for 15 min to completely remove cell debris. The serum was then aliquoted and stored separately at −80°C until used for analysis.

RNA isolation and quantitative real-time polymerase chain reaction (qRT-PCR) assay
----------------------------------------------------------------------------------

Total RNA was isolated from 2 mL of serum using Trizol (Invitrogen, Carlsbad, CA) following the protocol of the manufacturer. The quality and concentration of mRNA were detected in a multi-volume spectrophotometer system (Epoch, Biotek, Winooski, VT). Real-time PCR was done in triplicate, including no-template controls. Amplification of the appropriate product was confirmed by melting curve analysis after amplification. Relative expression of *ACTN4* was calculated using the comparative cycle threshold (CT) (2^−ΔΔCT^) method with glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) as the endogenous control to normalize the data.

Statistical analysis
--------------------

All statistical analyses were carried out using the SPSS statistical package, version 20.0 (IBM, SPSS, Chicago, IL) and graphs were plotted using Origin Pro 9.0. Continuous variables are described as the mean ±SD. The χ^2^ test was applied to analyze the association of *ACTN4* expression with clinicopathological characteristics. Receiver operating characteristic (ROC) curves were plotted and the area under the curve (AUC) was calculated. All tests were 2-sided; a *P* value less than 0.05 was regarded as significance.

Results
=======

Serum ACTN4 level in breast cancer and healthy controls
-------------------------------------------------------

The median values of serum *ACTN4* levels in 96 healthy controls and 128 breast cancer patients were 0.600 and 1.335, respectively. Serum levels of *ACTN4* were distinctly increased in BC patients compared with healthy individuals (1.318±0.360 *vs.* 0.644±0.400). Therefore, the serum levels of *ACTN4* were significantly elevated in BC patients (*P*\<0.05, [Figure 1](#f1-medscimonit-25-3298){ref-type="fig"}).

Correlation between *ACTN4* expression and clinical parameters of BC patients
-----------------------------------------------------------------------------

To further investigate whether the expression level of *ACTN4* was correlated the clinicopathological variables, the correlation of *ACTN4* expression with the clinical pathological data of the BC patients was assessed. The results revealed that *ACTN4* mRNA expression was obviously related to clinical stage (*P*=0.000), tumor grade (*P*=0.004) and lymph node status (*P*=0.024). No relationship was found between *ACTN4* and other clinicopathological parameters, including age, tumor size, ER status, PR status, and HER-2 status (all *P*\>0.05) ([Table 1](#t1-medscimonit-25-3298){ref-type="table"}).

The diagnostic value of serum *ACTN4* expression in BC
------------------------------------------------------

Receiver operating characteristic (ROC) curve analysis was used to estimate the predictive power and diagnostic accuracy of serum *ACTN4* levels for BC. The results showed that the area under the curve (AUC) was 0.887, with a sensitivity of 80.5% and specificity of 84.4% ([Figure 2](#f2-medscimonit-25-3298){ref-type="fig"}). The cutoff value for *ACTN4* expression level was 1.050. These outcomes indicated that *ACTN4* can be used to distinguish BC patients from healthy controls.

Discussion
==========

Breast cancer is the second most common cause of malignancy-associated death, after lung cancer, in women worldwide. BC is a heterogeneous disease because of its complicated etiology, including both genetic and environmental factors, such as family history, genetic defect, and immune system abnormalities \[[@b18-medscimonit-25-3298],[@b19-medscimonit-25-3298]\]. BC comprises multiple entities associated with distinctive histological and biological features, clinical presentations, and behaviors and responses to therapy. From the molecular point of view, breast cancer can be divided into 5 intrinsic molecular subtypes \[[@b20-medscimonit-25-3298],[@b21-medscimonit-25-3298]\]. The low survival rate shows the need to identify new diagnostic biomarkers for improving the therapeutic response and prognosis in BC patients to rationalize treatment decisions.

Alpha-actinins (ACTNs) are ubiquitously expressed proteins known to be cross-linked with filamentous actin (F-actin) to maintain cytoskeletal integrity and to control cell movement \[[@b22-medscimonit-25-3298]\]. Four ACTN family members, numbered 1--4, are present in humans and are highly conserved in other mammals \[[@b11-medscimonit-25-3298],[@b23-medscimonit-25-3298]--[@b25-medscimonit-25-3298]\]. ACTN4, an actin-bundling protein encoded by *ACTN4* gene, is widely expressed in a number of tissues, most notably glomerular podocytes \[[@b26-medscimonit-25-3298]\]. *ACTN4* has 1 actin-binding domain at the N-terminus, and *ACTN4* monomers can form a homodimer by binding in the opposite direction to form a dumbbell-shaped structure \[[@b27-medscimonit-25-3298]\]. The protein overexpression of *ACTN4* in cancer cells stimulates dynamic remodelling of the actin cytoskeleton, which is why *ACTN4*-overexpressing cancer cells have metastatic potential \[[@b12-medscimonit-25-3298]\]. Okamoto et al. showed that *ACTN4* is expressed in small-cell lung cancer (NSCLC) and is obviously related to distant metastasis \[[@b16-medscimonit-25-3298]\]. Miura et al. found that *ACTN4* is a promising predictive indicator for the efficacy of adjuvant chemotherapy in NSCLC \[[@b17-medscimonit-25-3298]\]. In salivary gland carcinoma, *ACTN4* expression level was increased and might be a contribute to the poor overall survival of patients \[[@b18-medscimonit-25-3298]\]. Therefore, it is important to explore the role of *ACTN4* in BC.

In our research, the expression of *ACTN4* was detected in 128 BC patients and 96 healthy controls, and it was demonstrated that *ACTN4* strongly differentiates BC patients from healthy controls. A highly significant increased expression of serum *ACTN4* was found in BC patients compared with that in healthy individuals. Moreover, receiver operating curve (ROC) analysis indicated that the AUC of *ACTN4* was 0.887 and the sensitivity and specificity at the optimal cutoff were 80.5% and 84.4%, respectively, indicating that it might be a promising biomarker for diagnosing BC. Hsu et al. reported that *ACTN4* is part of the BC cell motile apparatus and is highly expressed in the nucleus, suggesting a central role in BC tumorigenesis \[[@b28-medscimonit-25-3298]\]. Liu et al. also revealed that depletion of ACTN1 or ACTN4 suppresses the migration of BC cells \[[@b29-medscimonit-25-3298]\], consistent with our results.

We also analyzed the serum expression levels of *ACTN4* in relation to the different clinical pathologic characteristics in BC patients. The results showed that serum *ACTN4* expression was related with clinical stage, tumor grade, and lymph node status. However, there were no significant relationships between serum *ACTN4* expression and other features, including age, tumor size, ER status, PR status, and HER-2 status.

Several shortcomings in the present study should be acknowledged. Firstly, the sample size was relatively small, which might have reduced the statistical power of our results. Secondly, the study aimed to explore a biomarker for non-invasive detection of BC; therefore, the expression of ACTN4 protein in BC tissues and normal tissues was not detected by immunohistochemistry or Western blot methods. In addition, the present study was a primary study to explore the clinical significance of serum *ACTN4* for early diagnosis of BC. We found that the overexpression of *ACTN4* might contribute to aggressive progression of BC, but the molecular mechanisms underlying the oncogenic function of *ACTN4* in BC remain poorly defined. Therefore, further *in vitro* and *in vivo* experiments should be designed to address these issues.

Conclusions
===========

In summary, our data show that *ACTN4* expression levels are upregulated in BC patients. Moreover, the ROC results show the high diagnostic accuracy of *ACTN4*. The present findings suggest that serum *ACTN4* is a potentially useful biomarker for BC detection. Further research with larger samples involving validation and optimizing improvement should be conducted to confirm our results.
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![Serum *ACTN4* expression levels assessed by qRT-PCR in breast cancer patients (n=128) and healthy volunteers (n=96). The *ACTN4* expression levels were normalized to *GAPDH*. *ACTN4* expression was significantly higher in patients with breast cancer than that in healthy controls. Data shown as means ±SD (*P*\<0.05).](medscimonit-25-3298-g001){#f1-medscimonit-25-3298}

![ROC analysis for evaluation of the accuracy of serum *ACTN4* to discriminate patients with breast cancer from healthy controls. ROC -- receiver operating characteristic; AUC -- area under the curve.](medscimonit-25-3298-g002){#f2-medscimonit-25-3298}

###### 

Association of serum *ACTN4* expression with clinicopathological characteristics of breast cancer patients.

  Characteristics     No. (n=128)   *ACTN4* expression   χ^2^   *P* values   
  ------------------- ------------- -------------------- ------ ------------ -------
  Age (years)                                                                
   \<50               71            30                   41     1.065        0.302
   ≥50                57            19                   38                  
  Clinical stage                                                             
   I--II              83            41                   42     12.348       0.000
   III                45            8                    37                  
  Tumor grade                                                                
   I--II              79            38                   41     8.423        0.004
   III                49            11                   38                  
  Tumor size (cm)                                                            
   \<2                68            31                   37     3.278        0.070
   ≥2                 60            18                   42                  
  Lymph node status                                                          
   Negative           81            37                   44     5.110        0.024
   Positive           47            12                   35                  
  ER status                                                                  
   Negative           75            32                   43     1.474        0.225
   Positive           53            17                   36                  
  PR status                                                                  
   Negative           89            39                   50     3.793        0.051
   Positive           39            10                   29                  
  HER-2/neu status                                                           
   Negative           86            37                   49     2.494        0.114
   Positive           42            12                   30                  

ER -- estrogen receptor; PR -- progesterone receptor; HER2 -- human epidermal growth factor receptor 2.

[^1]: Study Design

[^2]: Data Collection

[^3]: Statistical Analysis

[^4]: Data Interpretation

[^5]: Manuscript Preparation

[^6]: Literature Search

[^7]: Funds Collection

[^8]: Cheng Fang and Juan-Juan Li are co-first authors
